Hazel James W, Slobogin Christopher
Vanderbilt University Medical Center.
Vanderbilt University.
Cornell J Law Public Policy. 2018;28(1):35-66.
Direct-to-consumer genetic testing (DTC-GT) companies have proliferated in the past several years. Based on an analysis of genetic material submitted by consumers, these companies offer a wide array of services, ranging from providing information about health and ancestry to identification of surreptitiously-gathered biological material sent in by suspicious spouses. Federal and state laws are ambiguous about the types of disclosures these companies must make about how the genetic information they obtain is collected, used, and shared. In an effort to assist in developing such laws, this Article reports a survey of the privacy policies these companies purport to follow. It canvasses ninety DTC-GT companies operating in the United States and provides a detailed analysis of whether and to what extent those policies inform consumers about how their genetic information will be used and secured, with whom it will be shared, and a host of other issues. Using the Federal Trade Commission’s articulation of the Fair Information Practice Principles and the agency’s proposed Privacy Framework as the baseline, we conclude that most policies fall well short of the ideal.
在过去几年里,直接面向消费者的基因检测(DTC-GT)公司大量涌现。基于对消费者提交的遗传物质的分析,这些公司提供各种各样的服务,从提供健康和血统信息到识别可疑配偶送来的秘密采集的生物材料。联邦和州法律对于这些公司必须就其获取的基因信息如何被收集、使用和共享所进行的披露类型含糊不清。为了协助制定此类法律,本文报告了对这些公司声称遵循的隐私政策的一项调查。它调查了在美国运营的90家DTC-GT公司,并详细分析了这些政策是否以及在多大程度上告知消费者其基因信息将如何被使用和保护、将与谁共享,以及许多其他问题。以联邦贸易委员会对公平信息实践原则的阐述以及该机构提议的隐私框架为基准,我们得出结论,大多数政策远未达到理想状态。